No Data
No Data
Pfizer Inc. Just Beat EPS By 61%: Here's What Analysts Think Will Happen Next
A Struggling Pfizer Looks for Help From a Wall Streeter
Andrew Baum, a Citigroup drug-company analyst and its head of global healthcare, hasn't had a Buy rating on Pfizer shares for over a decade, and he has pulled his target price down as the stock has fallen. But on Monday, Pfizer said it was hiring him to be its chief strategy and innovation officer.
Top Stock Reports for Amazon.com, Visa & Pfizer
Pfizer Options Spot-On: On May 10th, 119.35K Contracts Were Traded, With 3.21 Million Open Interest
On May 10th ET, $Pfizer(PFE.US)$ had active options trading, with a total trading volume of 119.35K options for the day, of which put options accounted for 60.97% of the total transactions, and call o
Stocks Surge On Healthy Earnings Season, Rising Jobless Claims: This Week In The Markets
It's been a quiet week in the markets, marked by a dearth of major economic news and a consistent flow of positive indicators from the first-quarter earnings season.As of May 7, 424 companies in the S
Express News | NYSE Order Imbalance 397936.0 Shares on Buy Side
No Data
JC88 : This jump not over yet… next week another covid wave